Amneal Spreads Bets On Generics Amid Focus On High-Barrier Opportunities
Generics Growth Supports Overall Increase In Q1 As Specialty Segment Falters
Amneal highlighted the benefits of a broad spread of generics and an increased shift towards complex products with high barriers to entry, as it reported generics sales growth in Q1 despite a tough operating environment for US generics.
You may also be interested in...
ANI Aims For CGT Top Spot With Two New Launches
ANI Pharmaceuticals has heralded the approval and launch of two new US competitive generic therapies as giving it a joint leadership position in the CGT space.
Amneal Expects Host Of New Launches To Drive Firm To Success
Despite a couple of setbacks during Q2, Amneal has sustained continual growth across its business, particularly in the injectables space.
Baclofen Deal Offers Amneal Biosimilars Advantage
Amneal says an $83.5m deal to acquire Saol Therapeutics’ baclofen franchise will also bring the firm an “experienced institutional commercial team” that will be able to support three biosimilar launches that the company now expects to execute in 2022.